Neoplasms, Germ Cell and Embryonal Clinical Trial
Official title:
Olaparib as Salvage Treatment for Cisplatin-resistant Germ Cell Tumor
This is open-label, single-arm, two-stage phase II trial of olaparib in patients with relapsed/refractory metastatic germ cell cancer. The primary objective is to evaluate the preliminary activity of Olaparib in GCT tumors. The secondary objective is to evaluate the safety of Olaparib in patients with cisplatin-refractory GCT.
This is a proof-of principle open-label, single-arm, two-stage phase II trial of olaparib 300 mg twice daily in patients with relapsed/refractory metastatic germ cell cancer. The study will recruit 10 patients, if no response is seen the study is terminated. If one or more responses are observed, further 19 patients (for a total of 29 patients) will be enrolled. If 4 or more of the first 29 evaluable patients have achieved objective response, further studies in patients with metastatic germ cell cancer are warranted. The main inclusion criteria are: - Patient with metastatic gonadal GCT or extragonadal GCT originating from retroperitoneum or mediastinum. - Disease progression during cisplatin-based chemotherapy or disease progression or relapse after high-dose chemotherapy or disease progression or relapse after at least 2 different cisplatin-based regimens - At least one measurable lesion that can be accurately assessed by CT/MRI/plain x-ray) at baseline and follow up visits. The study will be analyzed on an intent-to-treat basis. Secondary parameters will be analyzed exploratively for the intent-to-treat population. Correlations between with biomarkers (PAR, poly adenosine diphosphate-ribose polymerase (PARP-1), PTEN, XPA, ERCC1-3, XPF, FanD2, γ-H2AX) expression in paraffin-embedded tumor samples and clinical outcome will be performed in an exploratory intent. Plasma samples will be collected at baseline and at response/progression for possible retrospective biomarkers study. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02863003 -
Multicenter Database of Patients With Germ Cell Tumor
|
||
| Active, not recruiting |
NCT03911388 -
HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
|
Phase 1 | |
| Active, not recruiting |
NCT00393861 -
Study of Oxaliplatin Plus Bevacizumab in Germ Cell Tumor Patients
|
Phase 2 | |
| Completed |
NCT02679950 -
Understanding the Molecular and Genetic Differences Between Germ Cell Tumor at the Time of the Initial Diagnosis and at Late Relapse
|
||
| Completed |
NCT03403777 -
Avelumab in Refractory Testicular Germ Cell Cancer.
|
Phase 2 | |
| Recruiting |
NCT04949282 -
Spanish Series of Patients Treated With the Radionuclide Lutetium177
|
||
| Completed |
NCT03037385 -
Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Completed |
NCT04657315 -
Evaluation of Maximum Tolerated Dose, Safety and Efficiency of MSC11FCD Therapy to Recurrent Glioblastoma Patients
|
Phase 1/Phase 2 | |
| Withdrawn |
NCT02839694 -
Adjuvant Oral Decitabine and Tetrahydrouridine With or Without Celecoxib in People Undergoing Pulmonary Metastasectomy
|
Phase 1 | |
| Completed |
NCT03012620 -
Secured Access to Pembrolizumab for Patients With Selected Rare Cancer Types
|
Phase 2 | |
| Active, not recruiting |
NCT04222972 -
A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)
|
Phase 3 | |
| Completed |
NCT00611962 -
Phase II Study of Oxaliplatine-Paclitaxel in Patients With Metastatic Germ Cell Tumor Refractory to Cisplatin
|
Phase 2 | |
| Enrolling by invitation |
NCT04697446 -
External Control, Observational, Retrospective Study Comparing Pralsetinib to Best Available Therapy in Patients With RET-Fusion Positive NSCLC
|
||
| Terminated |
NCT02859415 -
Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in People With Primary Thoracic Malignancies or Carcinomas, Sarcomas or Germ Cell Neoplasms With Pleuropulmonary Metastases
|
Phase 1/Phase 2 | |
| Available |
NCT05592743 -
Vorasidenib Expanded Access Program
|